First Tracks Biotherapeutics Stock

First Tracks Biotherapeutics Liabilities

The The Liabilities of First Tracks Biotherapeutics (TRAX) as of Aug 14, 2026 is 43.06 M USD. In the previous year, The Liabilities was 50.30 M USD — a change of -14.40% (lower).

Liabilities

43.06 MUSD

YoY

-14.40%

Last updated:

In 2026, First Tracks Biotherapeutics's total liabilities amounted to 43.06 M USD, a -14.40% difference from the 50.30 M USD total liabilities in the previous year.

Access this data via the Eulerpool API
Get Free API Key

First Tracks Biotherapeutics Stock analysis

What does First Tracks Biotherapeutics do? First Tracks Biotherapeutics is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing First Tracks Biotherapeutics's Liabilities

First Tracks Biotherapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating First Tracks Biotherapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing First Tracks Biotherapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

First Tracks Biotherapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in First Tracks Biotherapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about First Tracks Biotherapeutics stock

The Liabilities of First Tracks Biotherapeutics is 43.06 M USD in 2026.

The Liabilities of First Tracks Biotherapeutics changed from 50.30 M USD to 43.06 M USD, representing a -14.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities First Tracks Biotherapeutics since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's First Tracks Biotherapeutics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — First Tracks Biotherapeutics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — First Tracks Biotherapeutics